Skip to main content
OpenTrials
Completed

NCT Number: NCT02022709

Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients

The purpose of this study is to evaluate the efficiency of SSRIs(Selective Serotonin Reuptake Inhibitor) ,ERP(Exposure and Response Prevention) and the combination of the two therapies for OCD(Obsessive-Compulsive Disorder) patients ,at the same time, to find out the biological or psychological predictors of treatment response in Chinese population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

16 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Shanghai Mental Health Center

Shanghai, Shanghai Municipality, 200030, China

About this study

Although Selective Serotonin Reuptake Inhibitors(SSRIs) and Cognitive Behavior Therapy (CBT) including Exposure and Response Prevention(ERP) are two kinds of the first line treatments for OCD(Obsessive-Compulsive Disorder) according to APA(American Psychological Association)guideline. Both of the treatments are effective, but few research has been done to find out who are more responsive to one treatment than the other. The aim of our research is to evaluate the efficiency of SSRIs ,ERP and the combination of the two therapies for OCD patients ,at the same time, to find out the biological and psychological predictors of treatment response in Chinese population.

This is a randomized, single-blind, cross-over design study.Approximately 60 patients will be randomized to SSRIs or ERP group. Neuropsychological assessment and fMRI(Functional Magnetic Resonance Imaging) will be performed at baseline,during the treatment and at the end of the study. The research has two period. In the first period(before week 8) ,the patients will have monotherapy. In the second period(after week 8), rates of improvement based on the YBOCS(Yale-Brown Obsessive Compulsive Scale) scores will be assessed. The patient will be considered responsive to treatment when he or she has a reduction in YBOCS score ≥ 35% of the score at the baseline.If the patient is responsive to the treatment that he or she has received at the first 8 weeks,he or she will continue to follow the previous treatment strategy.If not,the patient will have a combination of SSRIs and ERP treatment for another 8 weeks. The follow-up period will last up to 6 months.The result of the study will improve our knowledge about the efficacy of the two first line treatments .Also,it will help us to find out the predictors of the outcome of the two different kinds of treatments.Strategy of clinical treatment of OCD will be more individualized in the future.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Having been diagnosed with primary OCD as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-) criteria;Cleaning or checking as primary OCD symptoms
  • Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of ≥ 16
  • Never receiving adequate treatment or stop receiving treatment for at least 8 weeks
  • Having an education degree of high school or above
  • Accepting to participate in the study

Exclusion criteria

  • Having significant medical illnesses that would interfere with the conduct of the study
  • Clinically significant abnormal laboratory finding
  • Having comorbid psychiatric conditions according to the criteria set forth in the DSM-IV(administered by the Mini-International Neuropsychiatric Interview (MINI))
  • The current OCD symptoms are too severe that the patient cannot finish the evaluation or receive the ERP
  • Being currently at risk for suicide
  • Being pregnant or having the intention to be pregnant before the end of the study
  • A history of having inadequate response to adequate SSRIs or CBT treatment
  • Subjects who are unable to undergo the MRI

Treatment and study plan

Fluoxetine

Drug

The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.

Other names: Prozac

Sertraline

Drug

The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.

Other names: Zoloft

paroxetine

Drug

The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.

Other names: Seroxat

Citalopram

Drug

The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.

Other names: Cipramil

Fluvoxamine

Drug

The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.

Other names: Luvox

Exposure and Response Prevention

Behavioral

8 exposure and response prevention (ERP) sessions,once a week

Other names: Exposure and Rituals Prevention

Primary outcomes

  1. The change of Yale-Brown Obsessive-Compulsive Scale score

    Time frame: from baseline to month 6

    Patients were assessed at 0 week(w), 2w, 4w, 8w, 10w, 12w, 16w(0 month), 6 month

Secondary outcomes

  1. The change of Beck Depression Inventory(BDI) score

    Time frame: from baseline to month 6

    Patients were assessed at 0 week(w), 2w, 4w, 8w, 10w, 12w, 16w(0 month), 6 month

  2. The change of Beck Anxiety Inventory(BAI) score

    Time frame: from baseline to month 6

    Patients were assessed at 0 week(w), 2w, 4w, 8w, 10w, 12w, 16w(0 month), 6 month

  3. The change of Stress Perceived Questionnaire (PSS-10) score

    Time frame: from baseline to month 6

    Patients were assessed at 0 week(w),16w(0 month), 6 month

  4. The change of Behavioral Inhibition/Behavioral Activation System Scales score

    Time frame: from baseline to month 6

    Patients were assessed at 0 week(w), 16w(0 month), 6 month

  5. The change of Barratt Impulsiveness Scale 11 (BIS-11) score

    Time frame: from baseline to month 6

    Patients were assessed at 0 week(w), 16w(0 month), 6 month

  6. The change of Obsessive Beliefs Questionnaire-44(OBQ-44) score

    Time frame: from baseline to month 6

    Patients were assessed at 0 week(w), 16w(0 month), 6 month

  7. The NEO-Five Factor Inventory-Revised (NEO-FFI-R)

    Time frame: at baseline

    Patients were assessed at 0 week(w),

  8. The Early Trauma Inventory Self Report-Short Form(ETISR-SF)

    Time frame: at baseline

    Patients were assessed at 0 week(w)

Other outcomes

  1. Stop Signal Task (SST)

    Time frame: from baseline to month 6

    a measure of behavioral response inhibition

  2. fMRI(Functional Magnetic Resonance Imaging) - stop signal task

    Time frame: from baseline to month 6

    a measure of behavioral response inhibition

  3. C Reaction Protein(CRP)

    Time frame: from baseline to month 6

    for safety considerations

  4. Complete Blood Count

    Time frame: from baseline to month 6

    for safety considerations

  5. Liver and Kidney Function

    Time frame: from baseline to month 6

    for safety considerations

  6. Resting State Functional Magnetic Resonance Imaging

    Time frame: from baseline to month 6

    to quantify brain network

Sponsors and collaborators

Lead sponsor

Shanghai Mental Health Center

Other

Collaborators

  • Shanghai Jiao Tong University School of Medicine
  • Shanghai Municipal Science and Technology Commission

Registry information

Official study title

Efficacy of Exposure and Response Prevention(ERP) and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder

Important dates

Study start
2014
Primary completion
2017
Study completion
2018
First posted
Dec 30, 2013
Registry last updated
Sep 9, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.